---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-038747"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-08-17T20:15:41+00:00"
generated_at: "2026-08-17T20:17:40.833489+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma appoints Carol Brosgart, MD to board of directors

## Summary
- Carol Brosgart, MD appointed to board effective August 12, 2026.
- Brings decades of antiviral therapy and epidemiology experience; contributed to FDA-approved therapies.
- Previously held roles at Gilead Sciences and Tobira; served on multiple biotech boards.
- Will guide clinical development of CDI-988 for norovirus and broader antiviral pipeline.
- Currently on boards of Galmed, Eradivir, and Merlin Biotech.

## SEC filing metadata
- accession: 0001493152-26-038747
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-08-17T20:15:41+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226038747/0001493152-26-038747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226038747/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-038747
- JSON: https://secwatch.observer/filing/0001493152-26-038747.json
- Plain text: https://secwatch.observer/filing/0001493152-26-038747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.